Risankizumab vs vedolizumab after anti-TNF failure in UC

What is known

• Risankizumab targets the IL-23 p19 subunit. ¹
• Vedolizumab targets α4β7 integrin. ²

What is unknown / caveats

• No head-to-head comparison of risankizumab versus vedolizumab for 52-week clinical remission in anti-TNF–failed moderate-to-severe ulcerative colitis is present in the excerpts.
• The available data describe each agent's mechanism but provide no comparative remission outcomes between them.

References

1. Rommel FR, Bergheim C, Jerrentrup I, Weber S, Jenke A. Efficacy of Modified Upadacitinib Dosing in Pediatric Refractory IBD: A Case-Based Analysis. Children (Basel). 2025. PMID: 41007133.

2. Verdon C, Bessissow T, Lakatos PL. Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules. J Clin Med. 2019. PMID: 31817972.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.